Literature DB >> 11166283

[3H]dofetilide binding in SHSY5Y and HEK293 cells expressing a HERG-like K+ channel?

K Finlayson1, A J Pennington, J S Kelly.   

Abstract

The pharmacological characteristics of [3H]dofetilide binding in SHSY5Y, HEK293 and CHO-K1 cells were examined, and in parallel whole cell recordings used to characterise HERG-like K+ currents. Dofetilide affinity was similar in the human cell lines, SHSY5Y (Kd=99.6 nM) and HEK293 (Kd=102.9 nM), but 10 times lower in CHO-K1 cells (Kd=1200 nM). In contrast, clofilium and E4031 had a similar affinity in all three cell lines, whereas WAY 123,398 had no effect. Electrophysiological studies showed that SHSY5Y cells contained a HERG-like K+ current blocked by application of dofetilide to either side of the membrane. Block was faster when dofetilide was applied intracellularly. In contrast, HEK293 and CHO-K1 cells contained no such current, despite the presence of a partial cDNA for HERG in the former. That [3H]dofetilide is specific for I(Kr)/HERG may be questionable, as HEK293 and CHO-K1 cells contain no such functional K+ current.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11166283     DOI: 10.1016/s0014-2999(01)00731-2

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  9 in total

Review 1.  High throughput screening technologies for ion channels.

Authors:  Hai-bo Yu; Min Li; Wei-ping Wang; Xiao-liang Wang
Journal:  Acta Pharmacol Sin       Date:  2015-12-14       Impact factor: 6.150

2.  Kv 11.1 (hERG)-induced cardiotoxicity: a molecular insight from a binding kinetics study of prototypical Kv 11.1 (hERG) inhibitors.

Authors:  Z Yu; A P IJzerman; L H Heitman
Journal:  Br J Pharmacol       Date:  2014-12-15       Impact factor: 8.739

3.  Discovery of INCB8761/PF-4136309, a Potent, Selective, and Orally Bioavailable CCR2 Antagonist.

Authors:  Chu-Biao Xue; Anlai Wang; Qi Han; Yingxin Zhang; Ganfeng Cao; Hao Feng; Taisheng Huang; Changsheng Zheng; Michael Xia; Ke Zhang; Lingquan Kong; Joseph Glenn; Rajan Anand; David Meloni; D J Robinson; Lixin Shao; Lou Storace; Mei Li; Robert O Hughes; Rajesh Devraj; Philip A Morton; D Joseph Rogier; Maryanne Covington; Peggy Scherle; Sharon Diamond; Tom Emm; Swamy Yeleswaram; Nancy Contel; Kris Vaddi; Robert Newton; Greg Hollis; Brian Metcalf
Journal:  ACS Med Chem Lett       Date:  2011-10-05       Impact factor: 4.345

4.  Identification of human Ether-à-go-go related gene modulators by three screening platforms in an academic drug-discovery setting.

Authors:  Xi-Ping Huang; Thomas Mangano; Sandy Hufeisen; Vincent Setola; Bryan L Roth
Journal:  Assay Drug Dev Technol       Date:  2010-12       Impact factor: 1.738

Review 5.  Drug-induced torsades de pointes and implications for drug development.

Authors:  Robert R Fenichel; Marek Malik; Charles Antzelevitch; Michael Sanguinetti; Dan M Roden; Silvia G Priori; Jeremy N Ruskin; Raymond J Lipicky; Louis R Cantilena
Journal:  J Cardiovasc Electrophysiol       Date:  2004-04

6.  Pharmacokinetic-pharmacodynamic modelling of drug-induced QTc interval prolongation in man: prediction from in vitro human ether-à-go-go-related gene binding and functional inhibition assays and conscious dog studies.

Authors:  V F S Dubois; E Casarotto; M Danhof; O Della Pasqua
Journal:  Br J Pharmacol       Date:  2016-09-07       Impact factor: 8.739

Review 7.  Roles of K+ channels in regulating tumour cell proliferation and apoptosis.

Authors:  Zhiguo Wang
Journal:  Pflugers Arch       Date:  2004-03-27       Impact factor: 3.657

8.  Small molecule screening platform for assessment of cardiovascular toxicity on adult zebrafish heart.

Authors:  Satish Srinivas Kitambi; Erik S Nilsson; Petra Sekyrova; Cristian Ibarra; Gilbert Nyah Tekeoh; Michael Andäng; Patrik Ernfors; Per Uhlén
Journal:  BMC Physiol       Date:  2012-03-26

9.  Novel selective β1-adrenoceptor antagonists for concomitant cardiovascular and respiratory disease.

Authors:  Jillian G Baker; Sheila M Gardiner; Jeanette Woolard; Christophe Fromont; Gopal P Jadhav; Shailesh N Mistry; Kevin S J Thompson; Barrie Kellam; Stephen J Hill; Peter M Fischer
Journal:  FASEB J       Date:  2017-04-11       Impact factor: 5.191

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.